leisure time -WSS

leisure time

author：leisure time 2025-09-03 15:23:47 - browse：37

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Too many hospitalized Covid

WSS

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

ACIP vaccine advisory panel sees its vacancies filled

Ebola vaccine can save some who are already sick, per new study

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Supreme Court wrestles with OxyContin maker's bankruptcy deal

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

hotspot

leisure time

knowledge

Drug repurposing or repositioning? The language matters

After sickle

Activists slam private health insurers over coverage restrictions

Ebola vaccine can save some who are already sick, per new study

23andMe had bad news about my health. I wish a person had delivered it

Teach medical students about patients with intellectual disabilities

Medical leaders decry Supreme Court decision on affirmative action

Patients' immediate access to test results puts radiologists in a bind

In age of alternative facts, a scholarly course on calling out crap

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

entertainment

The woman behind the Dana Farber

Pharma patents targeted by Biden in move to slash drug prices

STAT letters to the editor on burnt

Too many hospitalized Covid

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

FDA approves world's first CRISPR

knowledge

hotspot

leisure time

hotspot